🔊 CEOInterviews
Start App
CEO / Investor / Company ⓘ
Topic or Keyword ⓘ
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Dikla Axselbrad

CEO, Polypid

Search every verified Dikla Axselbrad interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Dikla Axselbrad, CEO of PolyPid, stated in January 2026 that the company is transitioning from a development-stage to a commercial-stage company. She said PolyPid plans to submit a New Drug Application (NDA) early in 2026, with a rolling submission eligible under Breakthrough Therapy designation, and expects a PDUFA action date around early 2027. Axselbrad also noted that the company intends to announce a US deal in the coming months and advance its pipeline, including a GLP-1 product. In a 2022 interview, Axselbrad described her role as CFO as that of a "Chief Focus Officer" in an innovation company, emphasizing the need for consistency in long-term strategy and creativity in day-to-day operations. She stated that funding is the most critical missing element in the biotech industry due to the lengthy development journey.

Selected quotes

Recent appearances

  • PolyPid: Advancing a New Paradigm in Surgical Care | Dikla Akselbrad, Ori Warshavsky, Danny Sudwarts

    January 14, 2026 · 📺 1BusinessWorld

    Surgical site infections remain a major source of avoidable harm, delayed recovery, and hospital cost even when standard protocols are followed. This 2026 Global BioInnovation Forum session during JPM Week focuses on a localized, controlled release approach designed to deliver therapy precisely at the site of care and reduce post surgical complications. The discussion opens with the clinical and economic burden of infection across hospital settings, including the persistent infection rates seen in complex procedures such as open abdominal colorectal resections and breast reconstruction. The c…

    Watch on YouTube ↗

  • Ep607: Dikla Czaczkes Akselbrad | Executive Vice President and Chief Financial Officer, PolyPid

    April 01, 2022 · 📺 The Matias Experiment

    Dikla Czaczkes Akselbrad is the Executive Vice President and Chief Financial Officer of PolyPid, a global clinical-stage biopharmaceutical company focused on developing, manufacturing, and commercializing novel, locally administered therapies to improve surgical outcomes. Before joining PolyPid seven years ago, she served as CFO at both Compugen and Packet Technologies and as Audit Manager at Ernst & Young Israel. She holds an MBA in Finance and a BA in Accounting & Economics, both from Tel Aviv University, and is a certified public accountant in Israel.

    Watch on YouTube ↗